Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Maastricht – page 78

1 387 clinical trials in Maastricht, The Netherlands across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Maastricht at a glance
1 387
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 387 trials in Maastricht

Open in trial search

Graft versus host disease+1

Not recruiting

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Thymoma malignant

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Non-small cell lung cancer+2

Not recruiting

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Idiopathic pulmonary fibrosis+1

Not recruiting

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Spinal muscular atrophy

Not recruiting

Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Travere Therapeutics Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Colorectal cancer metastatic

Not recruiting

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Nouscom S.r.l.

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Maastricht

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer, and melanoma treatments. Studies include novel therapy combinations and personalized treatment approaches.

  • Advanced treatment protocols for metastatic conditions
  • Immunotherapy interventions
  • Diagnostic imaging improvements

Particular emphasis on targeted therapies and treatment optimization for various cancer types.

02 Chronic Disease Management

Research focusing on chronic kidney disease, fibromyalgia, and inflammatory bowel conditions. Studies evaluate new therapeutic approaches and treatment combinations.

  • Novel drug combinations
  • Disease progression monitoring
  • Quality of life improvements

Emphasis on developing effective long-term management strategies for chronic conditions.

03 Cardiovascular Studies

Investigations into peripheral arterial disease and cardiomyopathy treatments. Research includes innovative therapeutic approaches and preventive strategies.

  • Cardiovascular risk reduction
  • Treatment optimization
  • Disease prevention protocols

Focus on improving patient outcomes through targeted interventions and preventive measures.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.